Seeking Alpha
20 Nov 2026, 23:10 UTC · 1h ago
Pharvaris: Orally Available HAE Therapy Appears To Be Ideal All Court Player
Impact · against what's priced in
The article provides no new catalysts for PHVS, as the clinical efficacy and upcoming FDA decision are already baked into the current valuation. The highlighted competitive pressures further reinforce the existing risks to peak sales.
- PHVS+0.00
No priced-in read yet
- In context
The 83% attack reduction and the April 23, 2027 PDUFA date are recognized as already priced into the $2.25 billion valuation, offering no incremental movement.
Read from the article alone





